Impact of vitamins A, B, C, D, and E supplementation on improvement and mortality rate in ICU patients with coronavirus-19: a structured summary of a study protocol for a randomized controlled trial

This study will evaluate the main hypothesis that supplementation with vitamins A, B, C, D, and E significantly improves the severity and mortality rate in ICU patients with COVID-19.Trial designThis study is a randomized, single-blinded, two-arm (1:1 ratio) parallel group clinical trial.ParticipantsWe are conducting this study in patients with COVID-19 admitted to intensive care units at the Imam Khomeini Hospital Complex in Tehran, Iran.The inclusion criteria are as follows: (1) aged between 20 and 60  years, (2) both male and female patients with COVID-19, (3) clinical or definitive diagnosis (using polymerase chain reaction (PCR) test), (4) patients have not participated in other clinical trials, and (5) no renal or hepatic abnormalities.The exclusion criteria are as follows: (1) patients with specific and rare viral diseases such as HIV and (2) patients who have been undergoing chemotherapy for the past month.Intervention and comparatorDuration of intervention: 7  days from randomizationIntervention in the treatment group:Vitamin A 25,000  IU dailyVitamin D 600,000  IU once during studyVitamin E 300  IU twice dailyVitamin C is taken four times per dayB vitamins are taken as a daily Soluvit [which included thiamine nitrate 3.1  mg, sodium riboflavin phosphate 4.9 mg (corresponding to vitamin B2 3.6  mg), nicotinamide 40 mg, pyridoxine hydrochloride 4.9 mg (corresponding to vitamin B6 4.0  mg), sodium pantothenate 16.5 mg (corresponding to pantothen...
Source: Trials - Category: Research Source Type: clinical trials